Interventional device firm ev3 of Plymouth, MN, has received Food and Drug Administration 510(k) clearance to market its Protege EverFlex self-expanding stent system for the palliative treatment of malignant neoplasms in the biliary tree.
Additionally, ev3 obtained CE Mark approval for the product for general use in the peripheral vasculature, including common and external iliac, subclavian, and superficial femoral arteries, the company said.
By AuntMinnie.com staff writers
March 10, 2006
Related Reading
ev3 stent gets 510(k), October 21, 2004
Copyright © 2006 AuntMinnie.com